

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

### NICE Technology Appraisal No.314; Implantable cardioverter defibrillators and cardiac resynchronisation therapy (biventricular pacing)

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> <li>• Abbott</li> <li>• Biotronik UK</li> <li>• Boston Scientific</li> <li>• EBR systems</li> <li>• LivaNova</li> <li>• Medtronic UK</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Anticoagulation Europe</li> <li>• Arrhythmia Alliance</li> <li>• Atrial Fibrillation Association</li> <li>• Blood Pressure UK</li> <li>• British Cardiac Patients Association</li> <li>• Cardiomyopathy UK</li> <li>• Cardiovascular Care Partnership</li> <li>• Different Strokes</li> <li>• HEART UK</li> <li>• Muslim Council of Britain</li> <li>• Network of Sikh Organisations</li> <li>• Pumping Marvellous</li> <li>• Somerville Foundation</li> <li>• Stroke Association</li> <li>• Thrombosis UK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Nursing in Cardiovascular Care</li> <li>• British Association of Stroke Physicians</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Heart Rhythm Society</li> <li>• British Hypertension Society</li> <li>• British Nuclear Cardiology Society</li> <li>• British Society for Haematology</li> </ul>	<p><u>General commentators</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparators</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (amiodarone, bendroflumethiazide, diltiazem felodipine, fosinopril, furosemide, lisinopril, nevigolol, perindopril, ramipril, trandolapril verapamil)</li> <li>• Alliance Pharmaceuticals (Acenocoumarol, Chlortalidone)</li> <li>• Bayer (nifedipine, nimodipine)</li> <li>• Kent Pharmaceuticals (amiodarone)</li> <li>• LEO Laboratories (bumetanide)</li> <li>• Novartis Pharmaceutical UK (isradipine)</li> <li>• Roche (carvedilol cilazapril)</li> <li>• Sandoz (bisoprolol)</li> </ul>

<ul style="list-style-type: none"> <li>• British Society for Haemostasis and Thrombosis</li> <li>• British Society for Heart Failure</li> <li>• British Society of Cardiovascular Imaging</li> <li>• British Thoracic Society</li> <li>• Clinical Leaders of Thrombosis</li> <li>• Nurses Hypertension Association</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of Emergency Medicine</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science and Technology</li> <li>• Society for Vascular Nurses</li> <li>• Society for Vascular Technology</li> <li>• Society of Cardiothoracic Surgeons</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• Vascular Anaesthesia Society of Great Britain and Ireland</li> <li>• Vascular Society of Great Britain and Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Canterbury and Coastal CCG</li> <li>• NHS England</li> <li>• NHS Isle of Wight CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Sanofi Aventis (amiodarone, diltiazem metolazone)</li> <li>• Sigma Pharmaceuticals (amiodarone)</li> <li>• Teva UK (amiodarone)</li> <li>• UCB Pharma UK (moexipril, nifedipine)</li> <li>• Winthrop Pharmaceuticals UK (amlodipine, cilazapril, ramipril, indapamide)</li> <li>• Wockhardt UK (amiodarone, furosemide)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Heart Group</li> <li>• European Council for Cardiovascular</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Research</li> <li>• The Society for Research in Rehabilitation</li> <li>• Wellcome Trust</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>
---	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

### **STA Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.